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improvement in 2-year overall survival, suggesting TRT should 
be considered for all patients with ES-SCLC who respond to 
chemotherapy. An additional analysis showed that in patients 
with a response but residual disease after chemotherapy, the 
difference in 1-year survival was significantly better after 
TRT (Lancet 2015,385,1292-3). We carried out a European 
survey to determine the impact of the publication on clinical 
practice. 
 
Material and Methods: In May 2015 an electronic 
questionnaire of 34 items was composed using Select Survey 
software designed for running online surveys. Questions 
covered the use of TRT before and after the CREST study, 
evaluated the current practice of prophylactic cranial 
irradiation (PCI), including dose and fractionation, and asked 
whether practice was restricted based on performance status 
(PS) and age. The survey was distributed by email to one 
thoracic clinical/radiation oncologist per centre in 7 
European countries. A reminder was sent to non-responders. 
 
Results: This European-wide survey received 95 complete 
responses (UK n=42, Belgium n=23, Netherlands n=14, France 
n=8, Switzerland n=5, Germany n=2, Poland n=1). A response 
rate of 74% was achieved within the UK. Before the 
publication of the CREST study only 25% of centres were 
giving TRT routinely to patients who had responded to 
chemotherapy, compared to the current practice of 81%. 
Currently the preferred dose and fractionation of TRT is 30 
Gy in 10 fractions in 70% of centres, however a wide variety 
of fractionations were used before the CREST publication. An 
upper limit of PS ECOG 2 is commonly applied to TRT (83 %). 
In the 18 centres (19%) not implementing TRT there were a 
wide variety of explanations with no single reason standing 
out. Regarding the practice of PCI in ES-SCLC, 96% of centres 
give PCI routinely if patients have responded to 
chemotherapy. Of these, 52% deliver 25Gy in 10 fractions and 
44% deliver 20Gy in 5 fractions. An upper age limit was 
applied in 76% of all centres, the most common age limit 
being 75 (60 %). An upper limit for PS was applied in 88% of 
all centres, most commonly ECOG 2. 
 
Conclusion: Following the publication of the CREST study 
there has been a dramatic increase in the use of TRT in 
patients with ES-SCLC who have responded to chemotherapy. 
The dose and fractionation schedule used in the study has 
widely been adopted as standard practice across Europe. 
There is also evidence of high consistency in European 
practice in the use of PCI in patients with ES-SCLC. 
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Purpose or Objective: To compare acute skin toxicity 
between prone whole-breast irradiation (WBI) with a 
sequential boost (SeqB) and a simultaneous integrated boost 
(SIB). 
 
Materials and Methods: 167 patients were randomized 
between WBI with a SeqB or a SIB. 150 patients were treated 
at Ghent University Hospital (UZ Gent) and 17 at Liège 
University Hospital. All patients were treated in prone 
position to 40.05 Gy in 15 fractions to the whole breast. In 
the SeqB arm a median dose of 10 Gy in 4 fractions (negative 
surgical margins) or 14.88 Gy in 6 fractions (transsection) was 
prescribed to the PTV_boost (CTV to PTV margin of 5 mm). In 
the SIB arm a median dose of 46.8 or 49.95 Gy (negative and 
positive surgical margins, respectively) was prescribed to the 
CTV_boost with dose decay to 40.05 Gy in the first 2 cm 
around the CTV_boost. In the SeqB arm dose parameters 
were calculated on the summed plan (WBI + boost). For 
comparison, a PTV_optim was created including the PTV for 
WBI more than 2 cm away from the CTV_boost as illustrated 




Dermatitis was scored using the Common Toxicity Criteria for 
Adverse Events (CTCAE). Desquamation was scored as: none, 
dry or moist; pruritus as absent or present.  
 
Results: The analysis of dose parameters was done on 146 
patients treated at UZ Gent. Reasons for excluding patients 
were electron boost (2), 3 different plans on 3 different CTs 
(1) and changed treatment arm due to machine breakdown 
(1). This latter patient was excluded from the toxicity 
analysis as well. Patient age was the only significantly 
different parameter between treatment arms (mean age 59.6 
± 11.0 vs 55.7 ± 10.4 years, p=0.0210). Dose coverage of the 
CTV_boost was slightly better in the control arm (D95 of 98 ± 
1% vs 97 ± 2%, p<0.01). The volume of the PTV_optim and the 
skin receiving more than 105% of the prescription dose were 
significantly higher in the SeqB-arm than in the SIB-arm (27 ± 
20% vs 9 ± 6% for the PTV_optim and 394 ± 216cc vs 201 ± 
125cc for the skin, both p<0.01).In both arms, 6/83 patients 
developed moist desquamation (primary endpoint). Grade 
2/3 dermatitis was significantly more frequent in the SeqB 
arm (38/83 vs 24/83 patients, p=0.037). In the SIB and SeqB 
arm, respectively, 36 and 51 patients developed pruritus 
(p=0.015). The incidence of edema was lower in the SIB arm 
(59 vs 68 patients), but not statistically significant (p=0.071). 
 
Conclusion: Acute toxicity is not increased using a SIB in 
prone hypofractionated WBI. In contrast, grade 2/3 
dermatitis and pruritus are significantly less frequent. With 
our SIB-technique, high dose regions outside the boost region 
are smaller than with a SeqB. 
 
OC-0142  
Hypo- vs normofractionated radiation of early breast 
cancer in the randomised DBCG HYPO trial 
B.V. Offersen
1Aarhus University Hospital, Dept Oncology, Aarhus C, 
Denmark 
1, E.H. Jacobsen2, M.H. Nielsen3, M. Krause4, L. 
Stenbygaard5, I. Mjaaland6, A. Schreiber7, U.M. Kasti8, M.B. 
Jensen9, J. Overgaard10 
2Lillebaelt Hospital, Dept Oncology, Vejle, Denmark 
3Odense University Hospital, Dept Oncology, Odense, 
Denmark 
4University Clinic Carl Gustav Carus- Technical University 
Dresden, Clinic for Radiotherapy and Oncology, Dresden, 
Germany 
ESTRO 35 2016                                                                                                                                                    S65 
______________________________________________________________________________________________________ 
5Aalborg University Hospital, Dept Oncology, Aalborg, 
Denmark 
6Stavanger University Hospital, Dept Oncology, Stavanger, 
Norway 
7Academic Teaching Hospital Dresden-Friedrichstadt, Dept 
Oncology, Dresden, Germany 
8Kristiansand Hospital, Dept Oncology, Kristiansand, Norway 
9Copenhagen University Hospital, DBCG- Rigshospitalet, 
Copenhagen, Denmark 
10Aarhus University Hospital, Dept Experimental Clinical 
Oncology, Aarhus C, Denmark 
 
Purpose or Objective: Based on poor results using 
hypofractionated adjuvant radiotherapy (RT) of early breast 
cancer (BC) 50 Gy/25 fr. has been Danish Breast Cancer 
Group (DBCG) standard since 1982. Results from the UK and 
Canada stimulated a renewed interest in hypofractionation, 
and the non-inferiority DBCG HYPO trial was initiated. The 
hypothesis was that 40 Gy/15 fr (2.67 Gy/fr, 3 weeks) does 
not result in more grade 2-3 breast induration than 50 Gy/25 
fr (2.0 Gy/fr, 5 weeks) 3 years post RT. 
 
Materials and Methods: From 2009-2014 1868 patients >40 
years operated with breast conservation for early pT1-2 pN0-
1(mic) BC (n=1617) or DCIS (n=251) were enrolled irrespective 
of breast size, systemic therapy and boost, and randomized 
50 Gy/25 fr vs. 40Gy/15 fr. Strata were institution, breast 
size (≤ 600 ml vs. > 600 ml), systemic therapy and boost. The 
primary endpoint was grade 2-3 induration 3 years post RT, 
secondary endpoints were other normal tissue responses, 
genetic risk profile for RT-induced fibrosis and recurrences. 
ClinicalTrial NCT00909818. 
 
Results: 942 pts (50.4%) were assigned to the 50 Gy group 
and 926 (49.6%) to the 40 Gy group. Median age was 59 years 
(range 39-83). Median follow up was 3 years. The analysis was 
by intention to treat. Results are actuarial 3 year rates using 
morbidity in 1801 pts 1 yr post RT as baseline. 1086 pts (60%) 
had 3 year scores of morbidity and the rate of grade 2-3 
induration was 12.2%±1%. Grade 2-3 induration was seen in 
the 50 Gy group in 119 out of 904 pts with the rate 
14.2%±1.4%, and in the 40 Gy group in 97 out of 897 pts, the 
rate being 10.1% ±1%, representing a HR 1.27 (95% CI 0.97-
1.66), p=0.08. 859 pts (48%) had small breasts with a rate of 
grade 2-3 induration of 9.8%±1% compared to 14.3%±1% 
among 942 pts with large breasts, HR 1.56, (95% CI 1.18-
2.05), p=0.001. Among the 653 pts (36%) treated with 
chemotherapy (CT) the rate of grade 2-3 induration was 
12.4%±1%, whilst in the 1148 pts with no CT the rate was 
11.8%±2%, HR 0.98 (95% CI 0.74-1.30), p=0.90. In 423 pts 
(23%) treated with sequential boost (10-16 Gy/5-8 fr) the 
rate of grade 2-3 induration was 12.4%±1% compared to 
12.1%±1% among 1378 pts with no boost, HR 0.93 (95% CI 
0.67-1.29), p=0.65. Multivariate analysis using grade 2-3 
induration at 3 yr as endpoint and including 
hypofractionation, breast size, chemotherapy and boost 
identified large breast size as the only independent risk 
factor. Overall the 3 yr risk of loco-regional recurrence was 
0.3%±0.1%. In the 50Gy / 40 Gy group loco-regional 
recurrence was reported in 2 pts / 4 pts, distant failure 4 pts 
/ 3 pts, new contralateral cancer or DCIS 2 pts / 3 pts.  
 
Conclusion: Moderately hypofractionated whole breast 
irradiation in early node-negative BC or DCIS does not result 
in more grade 2-3 induration compared to normofractionated 
therapy. Large breast size is an independent risk factor for 
developing induration. The 3 yr loco-regional recurrence risk 
is very low. 
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Purpose or Objective: We report preliminary results from a 
Bayescian randomized trial of IMRT vs. PSPT , both given with 
concurrent chemotherapy, for locally advanced (stage II-IIIB) 
NSCLC. The purpose of the trial was to assess and compare 
the incidence and time to development of treatment failure 
defined as (1) grade ≥3 pneumonitis or (2) local failure, 
whichever occurred first in 12 month. 
 
Materials and Methods: The sample size for this trial (n=150) 
was based on the assumption that incidence would be log-
normally distributed and that IMRT would produce event 
rates of 30% at 6 mo and 40% at 12 mo, and PSPT would 
reduce the event rate by 10%. The Bayescian design was 
chosen so that more patients will be randomly allocated to 
the more effective of the two treatments. All patients must 
have been candidates for concurent chemoradiation, and all 
underwent 4D CT-based treatment planning. An IMRT and a 
PSPT plan were created for each patient. Patients were 
eligible for randomization only if both plans satisfied normal 
tissue constraints at the same prescription dose (74 Gy (RBE) 
if achievable , otherwise 66 Gy (RBE), where RBE is 1 for 
photons and 1.1 for protons) 
 
Results: Total 147 patients who were randomized to IMRT 
(n=90) or PSPT (n=57) and treated according to randomization 
were included for this analysis. Demographic characteristics 
were well balanced between the two arms. The GTV and PTV 
volumes were bigger in the PSPT arm though the difference 
was not statisically significant. More patients in PSPT arm 
received higher tumor dose. Patients in PSPT arm had larger 
volume of the lung receiving ≥30 -80 Gy (RBE) compared with 
IMRT patients, presumably due to the larger target volume 
and 3D nature of PSPT. The incidence of protocol failure at 
12 month were 20.7%, 15.6%, and 24.6% in all, in IMRT, and in 
PSPT patients, respectively. The median failure free survival 
times were 67.6, 67.6, and 69. 8 months in all, in IMRT, and 
in PSPT patients, respectively. Total of 12 patients developed 
grade ≥3 or higher RP, 6 in each arm. Two of the 6 patients 
had grade 5 RP in IMRT arm. The incidences of grade ≥3 RP 
were 8.7%, 7.2%, and 11.0% in all, in IMRT, and in PSPT 
patients, respectively. 
 
Conclusion: Considerably fewer events occurred in the 
evaulable randomized patients than were expected from 
historical experience. No statistical differences were found 
between IMRT vs. PSPT in the incidence of treatment failure, 
grade ≥3 pneumonitis, or local failure. Future analyses will 
involve comparing data from CT and PET images, blood 
samples and symptoms and their correlations with dose 
distributions to clarify factors affecting outcomes and to 
determine how physical and biological uncertainties affect 
proton dose distributions. *Supported in part by NCI grants 
P01 CA021230 and U19 CA021239. 
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Purpose or Objective: The role of prophylactic cranial 
irradiation (PCI) in limited disease (LD) small-cell lung cancer 
(SCLC) has proven to significantly decrease the incidence of 
